Molecularly anti-hrHPV Technology

SR BioPharma has focused on non-invasive approaches to persistent hrHPV infection for more than two decades. Through sustained research into HPV infection and virus–host interactions, the Group developed its proprietary Molecularly Targeted Anti-HPV Technology and translated it into the REBACIN® product portfolio.
Research on REBACIN® supports a device-led, dual-action approach: physical intervention against extracellular HPV as the primary mode of action, complemented by biological regulation of intracellular HPV E6/E7 expression.
A Device-Led Approach: Acting First on Extracellular HPV
Following local administration, REBACIN® forms an adhesive protective layer over the vaginal and cervical mucosa. Its functional components physically adsorb extracellular HPV particles, reduce virus–cell contact, and help inhibit viral entry.
Beyond Extracellular HPV: E6/E7 Regulation
As persistent hrHPV infection also involves infected epithelial cells, research has explored the ancillary biological activity of the AHP natural protein complex in REBACIN®. Studies indicate its function of regulating high-risk HPV oncogene expression, including HPV16/18 E6/E7.
 Together, these findings support intervention at two complementary levels:
Extracellular HPV — Physical Intervention
Mucosal coverage → HPV adsorption → reduced virus–cell contact → inhibited viral entry
HPV-Infected Cells — Ancillary Biological Regulation
Local biological activity → E6/E7 regulation → support for hrHPV clearance

Clinical & Real-World Evidence

Building on earlier clinical observations, a registration clinical rial was conducted at Peking Union Medical College Hospital and Hainan General Hospital from November 2014 to November 2015. REBACIN® achieved an overall response rate of 81.82% vs. 63.16% for the control product and an HPV clearance rate of 54.55% vs. 18.42%, respectively. No device-related adverse reactions or clinically significant irritation were reported, with good participant compliance.


Subsequently, a large-scale, prospective, multicenter real-world study evaluated REBACIN® in women with high-risk HPV infection across 239 medical institutions in 21 provinces and regions in China, with 4,539 cases included in the overall real-world database. Supportive Per-Protocol Set (PPS) analysis showed consistent findings, with HPV clearance rates of 60.64% in the REBACIN® group vs. 20.08% in the control group.


The real-world study also demonstrated favorable tolerability and safety, further supporting the clinical performance and benefit–risk profile of REBACIN® as a local, non-invasive approach to the management of persistent high-risk HPV infection.


Publication
To date, the REBACIN R&D team has published numerous high-impact-factor papers in international academic journals.

REBACIN® as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection

REBACIN® as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection

REBACIN® as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection
INT J CANCER.2019 NOV;145,2712-2719. IF：7.356
Download
Case Report: Noninvasive Clinical Intervention of REBACIN® on Histologic Regression of High Grade Cervical Intraepithelial Neoplasia

Case Report: Noninvasive Clinical Intervention of REBACIN® on Histologic Regression of High Grade Cervical Intraepithelial Neoplasia

Case Report: Noninvasive Clinical Intervention of REBACIN® on Histologic Regression of High Grade Cervical Intraepithelial Neoplasia
Front. Med., 2021 Jul 20;8:627355. IF：5.091
Download
REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients

REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients

REBACIN® is an optional intervention for persistent high‐risk human papillomavirus infection: A retrospective analysis of 364 patients
Int J Gynaecol Obstet. 2021 Jan;152(1):82-87. IF：3.561
Download
REBACIN® inhibits E6/E7 oncogenes in clearance of human papillomavirus infection

REBACIN® inhibits E6/E7 oncogenes in clearance of human papillomavirus infection

REBACIN® inhibits E6/E7 oncogenes in clearance of human papillomavirus infection
Front. Oncol.,2022 Dec 6:12:1047222. IF：5.738
Download
High-intensity focused ultrasound for patients with cervical intraepithelial neoplasia 2/3: A prospective one-arm study

High-intensity focused ultrasound for patients with cervical intraepithelial neoplasia 2/3: A prospective one-arm study

High-intensity focused ultrasound for patients with cervical intraepithelial neoplasia 2/3: A prospective one-arm study
Ultrasound Med Biol.2023 Jan;49(1):375-379. IF：3.694
Download
Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection:A real-world prospective multicenter cohort study

Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection:A real-world prospective multicenter cohort study

Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection:A real-world prospective multicenter cohort study
Gynecol. Oncol.2023 Nov:178:8-13. IF：4.7
Download
REBACIN® can remove high-risk Human Papillomavirus (HPV) persistent infection efficiently as an effective non-invasive treatment: a multicenter prospective stud

REBACIN® can remove high-risk Human Papillomavirus (HPV) persistent infection efficiently as an effective non-invasive treatment: a multicenter prospective stud

REBACIN® can remove high-risk Human Papillomavirus (HPV) persistent infection efficiently as an effective non-invasive treatment: a multicenter prospective stud
World J Surg Oncol. 2026 Apr 25. IF：2.5
Download

IPVC Presentation
REBACIN has participated in the conference for 12 consecutive sessions. At each conference, REBACIN has published research results, and was selected for giving oral presentations in 4 out of the 12 times.

Oral Presentation：

Pharmacokinetics of REBACIN Vaginal Delivery: Tissue Distribution, Nuclear Uptake, and Optimal Dosing for Enhanced Efficacy

37thTime：2025 10.23~10.26    |    Venue: Bangkok, Thailand     page：239-240

Proceedings Paper：

Prospective Real-World Study of Non-Invasive Clinical Intervention with REBACIN® for the Elimination of HrHPV Persistent Infection and CIN1Histologic Regression

36thTime：2024 11.12~15    |    Venue: Edinburgh, UK    page：459

Proceedings Paper：

Efficacy of REBACIN® Noninvasive Clinical Intervention in 3127 Patients with High-Risk Persistent HPV Infection

35thTime：2023 4.17~21    |    Venue: Washington, D.C., USA     page：719-720

Proceedings Paper：

Efficacy of REBACIN and Recombinant Human Interferon Alpha-2B on the Non-invasive Treatment of Clearing High-Risk Human Papilloma Virus Persistent Infection

34thTime：2021 11.15~19    |    Venue: Toronto, Canada (virtual)       page：200

Oral Presentation：

Real-World Evidence on Clinical Effect of REBACIN® as A Non-Invasive Intervention for High-Risk Human Papillomavirus Persistent Infection

Proceedings Paper：

A Noninvasive Clinical Intervention of REBACIN® for High-Risk Human Papillomavirus Persistent Infection

33rdTime：2020.7.20~24    |    Venue: Barcelona, Spain (virtual)       page：111、972

Oral Presentation：

Efficacy of REBACIN® Combination with ALA-PDT on the Treatment of HPV Induced Intraepithelial Neoplasian Regression of Cervical

Proceedings Paper：

Potent Efficacy of REBACIN® on Regression of Cervical Intraepithelial Neoplasia

32ndTime：2018.10.2~6    |    Venue: Sydney, Australia      page：1180

Proceedings Paper：

Efficacy and Safety of REBACIN® as Non-invasive Intervention Therapy for Sustained High Risk HPV (hrHPV) Infections

31stTime：2017.2.28~3.4    |     Venue: Cape Town, South Africa     page：426

Proceedings Paper：

Effectiveness of REBACIN® for Early Intervention on High Risk HPV Infection

30thTime：2015.9.17~21    |    Venue: Lisbon, Portugal     page：688

Proceedings Paper：

Efficacy of REBACIN® on Intervention of Sustained High Risk HPV (hrHPV) Infections

29thTime：2014.8.20~25    |    Venue: Seattle, USA     page：198

Proceedings Paper：

Effects of REBACIN® in Treatment of Cervical Intraepithelial Neoplasia (CIN) Following LEEP Procedure

28thTime：2012.11.30~12.6    |    Venue: San Juan, Puerto Rico     page：225

Oral Presentation：

Effect of REBACIN® in Treatment of High Risk HPV Infection

27thTime：2011.9.17~22    |    Venue: Berlin, Germany     page：164

Proceedings Paper：

Efficient suppression of E6 and E7 gene expression and the growth of HPV16/HPV18-induced tumor in mouse model by REBACIN®, a novel antiviral factor

26thTime：2010.7.3~8    |    Venue: Montreal, Canada     page：270